TRK-A, HER-2/neu, and KIT Expression/Activation Profiles in Salivary Gland Carcinoma.
Salivary duct carcinomas (SDCs) and adenoid cystic carcinomas (ACCs) are the most aggressive and the most frequent carcinomas of the salivary glands, respectively. Little is known about them in terms of molecular/biochemical characterization and conventional treatments are ineffective. On cryopreserved material, we analyzed the expression/activation status of TRK-A, HER-2/neu, and KIT receptors by means of immunoprecipitation and Western blot analysis experiments, and the presence of their cognate ligands by means of Western blot analysis and/or reverse transcription-polymerase chain reaction in 9 SDCs, 12 ACCs, and 8 normal glands. The amplification status of HER-2/neu was also investigated by means of fluorescent in situ hybridization analysis on fixed material. The receptor tyrosine kinase (RTK)-deregulated profile of the SDCs was characterized by the overexpression of activated TRK-A in the presence of its ligand, and the overexpression of HER-2/neu sustained by gene amplification. The RTK signature of the ACCs was represented by the overexpression of activated KIT and TRK-A and their cognate ligands, and the overexpression of activated HER-2/neu, in the absence of gene amplification, possibly sustained by epidermal growth factor receptor heterodimerization. In conclusion, SDCs and ACCs, although sharing TRK-A autocrine loop activation, have different pathologically activated RTK-deregulated profiles that may be potential targets for pharmacological RTK inhibitors.
Negri
Tiziana
T
Experimental Molecular Pathology Unit, Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Tamborini
Elena
E
Dagrada
Gian Paolo
GP
Greco
Angela
A
Staurengo
Samantha
S
Guzzo
Marco
M
Locati
Laura D
LD
Carbone
Antonino
A
Pierotti
Marco A
MA
Licitra
Lisa
L
Pilotti
Silvana
S
Am J Surg Pathol. 2007 Nov;31(11):1683-94
18059225
J Biol Chem. 2000 Feb 25;275(8):5388-94
10681513
Nature. 2003 Feb 13;421(6924):756-60
12610629
Invest New Drugs. 2005 Jan;23(1):31-7
15528978
Ann Anat. 1998 Apr;180(2):157-63
9587639
Prostate. 1998 Aug 1;36(3):172-80
9687989
Clin Cancer Res. 2001 Aug;7(8):2237-45
11489797
Clin Cancer Res. 2004 Feb 1;10(3):944-6
14871971
Lancet Oncol. 2002 Mar;3(3):137-44
11902499
Clin Cancer Res. 2004 Feb 1;10(3):938-43
14871970
J Clin Oncol. 2005 Jan 20;23(3):585-90
15659505
J Laryngol Otol. 2009 Feb;123(2):250-2
18405406
Int J Cancer. 1999 May 5;81(3):417-27
10209957
Cancer Res. 1994 Nov 1;54(21):5675-82
7522962
Science. 1987 Jan 9;235(4785):177-82
3798106
Mol Cancer Ther. 2003 May;2(5):471-8
12748309
Breast Cancer Res Treat. 2003 Jul;80(2):207-14
12908824
Histopathology. 2003 Apr;42(4):348-56
12653946
J Urol. 2004 Oct;172(4 Pt 1):1545
15371892
Prostate. 2000 Oct 1;45(2):140-8
11027413
J Histochem Cytochem. 1994 Nov;42(11):1417-25
7523489
Head Neck. 1997 Mar;19(2):126-33
9059870
Oncol Rep. 2001 May-Jun;8(3):477-84
11295066
Mol Cell Biol. 1989 Jan;9(1):24-33
2927393
Cancer Lett. 2000 Jun 1;154(1):107-11
10799746
J Craniomaxillofac Surg. 1997 Dec;25(6):328-34
9504310
Pathol Res Pract. 2001;197(9):621-6
11569926
Head Neck. 2008 May;30(5):680-3
17972317
Clin Cancer Res. 1998 Aug;4(8):1887-98
9717816
Clin Cancer Res. 2004 Dec 15;10(24):8214-9
15623596
Mod Pathol. 2000 Nov;13(11):1238-43
11106082
Head Neck. 2007 Oct;29(10):907-12
17563907
Mod Pathol. 1999 Oct;12(10):956-60
10530560
Histopathology. 2004 Mar;44(3):301-2
14987238
Clin Cancer Res. 2003 Sep 15;9(11):4132-8
14519636
Histopathology. 2007 Jul;51(1):114-5
17532773
Gastroenterology. 2004 Jul;127(1):294-9
15236194
J Oral Maxillofac Surg. 2006 Apr;64(4):636-41
16546643
Int J Biol Markers. 1999 Apr-Jun;14(2):68-72
10399625
Hum Pathol. 2002 May;33(5):484-95
12094373
Hum Pathol. 1996 Jun;27(6):561-6
8666365
J Clin Oncol. 2007 Mar 1;25(7):884-96
17327610
Oral Oncol. 2005 Oct;41(9):934-9
16054424
Oncogene. 2003 Aug 28;22(36):5592-601
12944907
Oral Oncol. 2007 Jan;43(1):33-6
16757202
Cancer Lett. 2006 Jan 28;232(1):90-8
16242838
Oncogene. 2005 Jul 28;24(32):5108-18
15870692